Elite Pharmaceuticals, Inc.
ELTP
$0.40
$0.000.73%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.70% | 332.85% | -134.62% | 256.06% | 1.31% |
| Total Depreciation and Amortization | -0.76% | 0.55% | -2.34% | 6.31% | -11.54% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -93.36% | -119.28% | 746.04% | -135.42% | -16.08% |
| Change in Net Operating Assets | -268.62% | 45.72% | 24.25% | -263.95% | -14.05% |
| Cash from Operations | -203.41% | -65.46% | 277.13% | 468.34% | -173.02% |
| Capital Expenditure | -99.52% | 52.66% | 71.06% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -99.52% | 52.66% | 71.06% | -- | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 53.55% | 93.55% | -2,542.80% | 19.06% | 39.79% |
| Issuance of Common Stock | -39.87% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 71.16% | 97.18% | -2,915.11% | 29.05% | 39.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -212.97% | -53.16% | 244.48% | 340.84% | -208.94% |